All In Biotech

Drug Trial Radar · NCT01363648

The Efficacy of Gliatiline® on Post-stroke Patients With Vascular Cognitive Impairment no Dementia

A Randomized, Double-blind, Placebo-controlled Phase IV Trial for an Evaluation of the Efficacy of Gliatiline® on Post-stroke Patients With Vascular Cognitive Impairment no Dementia

Last checked: Nov 20, 2026Latest source record: Oct 14, 2013 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 222 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

222

Actual

Start

Nov 2010

Primary completion

Mar 2013

Study completion Mar 2013

Sponsor

Lead sponsor
Seoul National University HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jun 1, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 25 years, up to 84 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To date, there are no approved treatments for vascular cognitive impairment (VCI) and the main therapeutic efforts are aimed at controlling vascular risk factors for countering VCI development or progression. Several studies have reported cholinergic deficits in brain and cerebrospinal fluid of patients with VCI. The effect of choline alphoscerate in clinical studies of Alzheimer's disease and VCI improved memory and attention impairments. The purpose of our study is to determine effectiveness of choline alphoscerate vs placebo in improving cognition in post-stroke patients with VCI-non dementia (VCI-ND).

Conditions

  • Cognitive Impairment
  • Stroke

Interventions

  • choline alfoscerateDrug

    Participants were randomly assigned to twice-daily doses of 400mg choline alphoscerate (alpha-glyceryl phosphoryl choline, Gliatilin®)

  • placebo (for choline alphoscerate)Drug

    Pill manufactured to mimic choline alfoscerate 400mg tablet

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. the change of K-TMT-e A of K-VCIHS-NP in the choline alfoscerate vs the placebo groups.Time frame: 12 weeks after taking drugs

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Seoul National University Bundang

    Seongnam, Gyeoinggido, South Korea

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.